Mark Flood
Psychiatry · Hackensack, NJNPI 1376729046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 722 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,981 and has fallen 50.7% since, to $976 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 722 payments — averaging $13.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Bausch Health US, LLC$796
- Takeda Pharmaceuticals U.S.A., Inc.$698
- Otsuka America Pharmaceutical, Inc.$666
- Neurocrine Biosciences, Inc.$656
- plus $4K from 21 others
What the payments were for
- Food & beverage$9,29399%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 104 | $1,244 |
| AbbVie(2 entities) | 149 | $1,125 |
| Bausch Health US, LLC | 54 | $796 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $698 |
| Otsuka America Pharmaceutical, Inc. | 42 | $666 |
| Neurocrine Biosciences, Inc. | 45 | $656 |
| Lundbeck LLC | 44 | $612 |
| Sunovion Pharmaceuticals Inc. | 39 | $543 |
| Alkermes, Inc. | 33 | $529 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $406 |
| Almatica Pharma LLC | 27 | $377 |
| Supernus Pharmaceuticals, Inc. | 21 | $315 |
| Vanda Pharmaceuticals Inc. | 19 | $291 |
| Tris Pharma Inc | 9 | $145 |
| Idorsia Pharmaceuticals US Inc | 9 | $140 |
| Neos Therapeutics, LP | 9 | $138 |
| Axsome Therapeutics, Inc. | 5 | $131 |
| Johnson & Johnson | 9 | $129 |
| Corium, LLC | 8 | $124 |
| Ironshore Pharmaceuticals Inc. | 7 | $101 |
| Noven Therapeutics, LLC | 6 | $87 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Eisai Inc. | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Vertical Pharmaceuticals, LLC | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$9,391 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 17 | $28,418 |
| RexultiBrexpiprazole | 14 | $25,082 |
| Wellbutrin XlBupropion Hcl | 11 | $21,493 |
| ZoloftSertraline Hcl | 19 | $14,576 |
| TrintellixVortioxetine Hydrobromide | 20 | $13,336 |
| ClozarilClozapine | 13 | $11,943 |
| RisperdalRisperidone | 38 | $10,770 |
| LexaproEscitalopram Oxalate | 23 | $9,693 |
| FetzimaLevomilnacipran Hcl | 16 | $7,777 |
| Loreev XrLorazepam | 12 | $5,242 |
| Aripiprazole | 157 | $4,324 |
| Zolpidem Tartrate | 53 | $3,145 |
| Duloxetine Hcl | 90 | $2,570 |
| Bupropion XlBupropion Hcl | 130 | $2,431 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 107 | $2,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Lexapro, Fetzima | $1,125 | $45,88956 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $666 | $25,08214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $698 | $13,33620 claims |
| Johnson & JohnsonRisperdal | $129 | $10,77038 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $377 | $7,015247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Hackensack
- Gary SmallHackensack$170K
- Syed ZaidiHackensack$57K
- Joseph AcquavivaHackensack$12K
- Daniel CarreroHackensack$8K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Shankar SrinivasanParsippany$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.